Christopher J. Silber

Chris joined Nocion in August 2020 as Chief Medical Officer, bringing more than 25 years of industry experience and a track record of clinical-regulatory success, developing novel therapeutics.

Before joining Nocion, Chris most recently served as Senior Vice President at Sage Therapeutics where he led clinical development efforts for zuranolone (SAGE-217) for depression indications, and the approval of ZULRESSO™ for post-partum depression. Prior to Sage, Chris served as Chief Medical Officer for Agilis Biotherapeutics (now a subsidiary of PTC Therapeutics), leading gene therapy efforts for rare diseases of the CNS.

During his earlier tenure at Lundbeck (and former Ovation Pharmaceuticals), he led development teams to the approval and commercialization of SABRIL® and ONFI®. Prior to Ovation, he held executive roles of increasing responsibility in clinical research with focus in neuroscience and analgesia at Takeda, Hospira, Abbott and Forest Laboratories.

Chris received his B.A. degree from Tufts University, an M.D. from the State University of New York at Buffalo, and post-graduate training in family medicine at Duke University Medical Center.